A man infected with human immunodeficiency virus (HIV) presented with a few-month history of an enlarging friable growth on the medial area of the left foot and a one-week history of bilateral lower extremity edema. Clinical and histologic examination led to a diagnosis of bacillary angiomatosis, and the patient responded to antibiotic therapy. We provide an overview of bacillary angiomatosis, a rare disorder that affects immunocompromised patients with CD4 cell counts less than 100/µL.

Case Report
A 45-year-old black man whose medical history included human immunodeficiency virus (HIV) infection, endocarditis, congestive heart failure, intravenous drug abuse, end-stage renal disease, sinusitis, and pneumonia presented with a few-month history of a progressively enlarging growth on the left foot (a growth that bled with mild trauma).
and a one-week history of bilateral lower extremity edema. The patient’s medications included methadone, temazepam, zolpidem, calcium carbonate, calcitriol, folic acid, multivitamin, ferrous sulfate, and trimethoprim-sulfamethoxazole.

On physical examination, the patient was afebrile and had normal mucous membranes, brittle fingernails, generalized xerosis, “track marks” on the left upper extremity, bilateral lower extremity pitting edema that was tender and warm to the touch, and a 1-cm well-circumscribed hemorrhagic nodule on the medial area of the left foot (Figure).

Results of laboratory studies were a leukocyte count of $7.3 \times 10^3/\mu L$ (reference range, $4.8–11 \times 10^3/\mu L$), a CD4 lymphocyte count of 107 cumulative cells (reference range, $400–1770$ cumulative cells), a CD8 lymphocyte count of 2292 cumulative cells (reference range, $240–1200$ cumulative cells), and no growth of any organisms in 3 serial serum blood cultures. Findings from bilateral lower extremity x-rays and Doppler ultrasounds were normal. The differential diagnoses that were considered included pyogenic granuloma, hemangioma, Kaposi sarcoma, papular angiokeratoma, arteriovenous malformation, hemangiopericytoma, vasculitis, thrombophlebitis, and an infectious etiology.

A biopsy specimen taken from the nodule on the medial area of the left foot contained a lobe of proliferating capillaries, venules, and neutrophils and an interstitial bacillary deposit. A Warthin-Starry silver stain tested positive for bacilli.

An initial diagnosis of cellulitis was made, and the patient was treated with amoxicillin. After a final diagnosis of bacillary angiomatosis was made, the antibiotic regimen was changed to erythromycin 500 mg 4 times a day. The hemorrhagic nodule cleared after 8 weeks of therapy. The patient was then lost to follow-up.

Comment
First described in 1983 by Stoler et al, bacillary angiomatosis is an angioproliferative disease that often occurs with severe immunodeficiency, as in advanced acquired immunodeficiency syndrome.\(^2\,^3\) This disease has been found in patients with acute myeloblastic leukemia, chronic lymphocytic leukemia, and organ transplants.\(^2\,^4\) Bacillary angiomatosis usually manifests as cutaneous tumors but also may manifest as systemic disease.\(^4\) The name of this disease was derived from the proliferating blood vessels seen in histologic specimens and from the presence of numerous bacillary organ-
isms detected with Warthin-Starry silver stain or electron microscopy.2

Although Bartonella infections are not uncommon, bacillary angiomatosis is a rare (or underdiagnosed) disorder—1.2 cases per 1000 patients infected with HIV.2 Patients affected most are those with CD4 cell counts less than 100/µL.2 Regular use of antibiotics may account for the rarity or underdiagnosis of this disease in patients infected with HIV.2

The first reported case of infection with organisms of Rochalimaea genus, now known as Bartonella, occurred during World War I and was termed trench fever.2 Transmission was through the bite of the human body louse.3 In 1990, Relman et al.6 recognized a relation between trench fever and Rochalimaea quintana, now known as Bartonella quintana, the cause of bacillary angiomatosis. Transmission through the body louse vector accounts for the association of B. quintana infection with homelessness.2 In 1992, another member of the genus Bartonella, B. henselae, also was recognized as an etiologic agent of this illness.2 B. henselae is transmitted to humans through direct contact with cats or cat fleas, Ctenocephalides felis.2 B. quintana is responsible for most cases of subcutaneous infection, deep soft-tissue disease, and lytic bone lesions.5 Liver and lymph node involvement have been associated with B. henselae infection.5 Bartonella species are fastidious gram-negative bacteria.3

Bacillary angiomatosis can present typically and atypically. Typical presentation is an inflammatory disease most often involving the skin.2 One or multiple skin lesions can develop, and these can be localized in cutaneous and subcutaneous tissues.2 The usual lesion is an anigmatosus papule or nodule resembling a pyogenic granuloma or a subcutaneous nodule with or without ulceration.7 Atypical presentation resembles Kaposi sarcoma or papular angio keras otoma.7 Other areas of involvement could include the oral, anal, conjunctival, and gastrointestinal mucosal surfaces, as well as the brain, respiratory tract, liver, spleen, bone, bone marrow, and lymph nodes.2,5 Lesions evolve slowly over several weeks, and patients usually complain of fever, weight loss, chronic lymphadenopathy, and, sometimes, abdominal pain.2,4

Typical findings of the histologic examination of bacillary angiomatosis consist of an atrophic or ulcerated epidermis with pseudo-epitheliomatous hyperplasia and lobes of proliferating small blood vessels containing cuboidal endothelial cells with or without atypical nuclei.2,7 Also found is a mixed inflammatory cell infiltrate predominated by vessel-surrounding neutrophils.7,7 Blood vessels can proliferate superficially or deep.7 Superficially proliferating vessels resemble a pyogenic granuloma or papular angio keratoma; deep-proliferating vessels resemble a histiocytoid hemangioma with a proliferation of small blood vessels lined by protuberant endothelial cells adhering to one another in an “epithelioid” pattern.7 The granular material found beside blood vessels is bacteria, which stains black with Warthin-Starry silver stain.7 Bartonella species also may be detected with immunohistochemistry, using anti-Bartonella species immune sera.4 Positive factor XIIIa dermal dendrocytes have been found in bacillary angiomatosis.7 Fibrous long-spacing collagen, a distinct ultrastructural collagen present in normal tissue, is abundant in various tumors, including those of bacillary angiomatosis.8 This collagen is found adjacent to Bartonella organisms and to endothelial cells.8

The diagnosis of bacillary angiomatosis is established by clinical and histologic examination of affected tissues.2 Culture of Bartonella species from serum is insensitive, and very few isolates are available worldwide.4 Polymerase chain reaction amplification is another method used in detecting Bartonella species in biopsy specimens.4

Bacillary angiomatosis can be cured with appropriate antibiotic therapy.4,5 Erythromycin 2 g/d is the treatment of choice, and doxycycline 100 mg twice a day is alternative therapy.4,5 Treatment of immunocompromised patients should be continued for 2 to 3 months.4,5 Not uncommonly, patients with bacillary angiomatosis relapse after withdrawal of antibiotic therapy.4 Precautionary measures that should be taken with immunocompromised patients include avoidance of contact with cats, fleas, and lice.4 Permethrin 1% dusting powder, the agent of choice for delousing, should be applied to clothing and bedding.4

Maintaining a high level of clinical suspicion is the most important aspect of diagnosing bacillary angiomatosis in immunocompromised patients. As this disease can be cured, recognition is important; untreated, bacillary angiomatosis can be fatal.

REFERENCES
Bacillary Angiomatosis


DISCLAIMER
The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients.

FACULTY DISCLOSURE
The Faculty Disclosure Policy of the College of Medicine requires that faculty participating in a CME activity disclose to the audience any relationship with a pharmaceutical or equipment company that might pose a potential, apparent, or real conflict of interest with regard to their contribution to the program. It is required by the Accreditation Council for Continuing Medical Education that each author of a CME article disclose to the participants any discussion of an unlabeled use of a commercial product or device or an investigational use not yet approved by the Food and Drug Administration.

Drs. Hoffman, Papadopoulos, Palmer, Austin, and Gropper report no conflict of interest. Dr. Fisher reports no conflict of interest.